Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.51 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PER2 | O15055 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024381 | 0.83 | RAD52 (0.47) | RAD52NLRP1BACE1MEN1KMT2A | |
| SCHEMBL606776 | 0.80 | RAD52 (0.57) | RAD52NLRP1BACE1MEN1KMT2A | |
| SCHEMBL6819364 | 0.78 | RAD52 (0.76) | RAD52NLRP1BACE1MEN1KMT2A | |
| SCHEMBL6816191 | 0.78 | RAD52 (0.76) | RAD52NLRP1BACE1MEN1KMT2A | |
| SCHEMBL609875 | 0.78 | CNR2 (0.45) | RAD52NLRP1PER2ALDH1A1LMNA | |
| SCHEMBL5028634 | 0.77 | RAD52 (0.41) | RAD52NLRP1MEN1KMT2APER2 | |
| SCHEMBL16604024 | 0.76 | RAD52 (0.74) | RAD52NLRP1BACE1MEN1KMT2A | |
| SCHEMBL1306615 | 0.76 | MEN1 (0.70) | RAD52NLRP1MEN1KMT2AALDH1A1 | |
| SCHEMBL607619 | 0.73 | LMNA (0.81) | RAD52NLRP1MEN1KMT2AALDH1A1 | |
| SCHEMBL28589907 | 0.72 | RAD52 (0.72) | RAD52NLRP1MEN1KMT2APER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | claimed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | claimed |
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | disclosed |
| US-8053436-B1 | 9-(piperazinylalkyl) carbazoles as bax-modulators | MERCK SERONO SA (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | BCL2, BAX, BAD | RAD52 3656/4885NLRP1 2445/4885BACE1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.